argenx SE (NASDAQ:ARGX) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Beth DelGiacco - Vice President of Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Derek Archila - Wells Fargo Tazeen Ahmad - Bank of America Rajan Sharma - Goldman Sachs Yatin Suneja - Guggenheim Akash Tewari - Jefferies Thomas Smith - SVB Security Danielle ...

First Quarter 2023 Financial Results and Business Update May 4, 2023 Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain ...

argenx • Together We Discover Corporate Presentation April 2023 Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain all o ...

Exhibit 99.1 argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patient ...

Financial Position - As of December 31, 2022, cash and cash equivalents amounted to $800.7 million, while total capital was $4,316.5 million[978]. - The company has no financial debt, which mitigates interest rate risk on borrowings[978]. - The company raised approximately $662 million from a global offering of 2,333,334 ordinary shares, including ADSs[996]. - The net proceeds from the offering have been invested in cash and cash equivalents and current financial assets[997]. Interest Rate and Currency Risk - For the year ended December 31, 2022, a 25 basis points change in interest rates would have a positive/negative impact of $6.2 million[984]. - On December 31, 2022, a 10% increase/decrease in the EUR/USD exchange rate would have resulted in a negative/positive impact of $61.39 million[985]. Credit Risk Management - The company has adopted a policy to only deal with creditworthy counterparties, minimizing credit risk exposure[979]. - The provision for expected credit losses was not significant, as there have been no credit losses over the last three years[980]. - The company has a significant concentration of credit risk due to a limited number of collaboration and license partners[979]. Liquidity Risk Management - The company maintains liquidity risk management by monitoring cash flows and maintaining adequate reserves[982].

argenx SE (NASDAQ:ARGX) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Tazeen Ahmad - Bank of America Securities Rajan Sharma - Goldman Sachs Thomas Smith - SVB Securities Brendan Smith - Cowen Yatin Suneja - Guggenheim Partners Myles Minter - William Blair Manos Mastorakis - Deutsche Bank Alex Nackenoff - Raymond James Allison Bratze ...

Fourth Quarter and Full Year 2022 Financial Results and Business Update March 2, 2023 Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusi ...

argenx SE (NASDAQ:ARGX) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Danielle Brill - Raymond James Yaron Werber - Cowen Yatin Suneja - Guggenheim Partners Derek Archila - Wells Fargo Allison Bratzel - Piper Sandler Akash Tewari - Jefferies Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Securities Thomas Smith - SV ...

Financial Performance - Argenx reported Q2 2022 net product revenues of $75 million[9], primarily driven by VYVGART sales[25] - US product net sales were $73.2 million in Q2 2022[20] - Japan product net sales were $1.5 million in Q2 2022[20] - The company ended Q2 with $2.6 billion in cash[7, 21] - R&D expenses for the second quarter were $126.9 million[21] - SG&A expenses for the second quarter were $127.8 million[21] VYVGART Launch and Expansion - Approximately 1400 patients are on VYVGART globally[27] - 85% of covered lives have broad coverage for VYVGART[34] - A J-Code for VYVGART went into effect on July 1, 2022[34] Pipeline Progress - A BLA submission for subcutaneous efgartigimod (SC) in gMG is expected by the end of 2022[7, 11] - ADHERE (CIDP) data is expected in Q1 2023[7] - ADVANCE-SC (ITP) and ADDRESS (PV) data are expected in the second half of 2023[7]